Core Insights - Sera Prognostics, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, focusing on its achievements in maternal and neonatal health [1] - The company specializes in innovative pregnancy biomarker information, particularly through its PreTRM® Test, which predicts the risk of spontaneous preterm birth [1] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through precision pregnancy care [1] - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test for early risk prediction of spontaneous preterm birth [1] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [1] - The 2025 March of Dimes Report Card indicates that the U.S. has received a D+ grade for preterm birth for four consecutive years, marking the longest stretch of the lowest grade in history [1] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion for 2016 [1] PreTRM® Test Details - The PreTRM Test measures proteins in the blood that are highly predictive of preterm birth, allowing for individualized risk assessment during weeks 18 to 20 of pregnancy [1] - This test enables physicians to make informed clinical decisions based on each woman's individual risk [1]

Core Viewpoint - A shareholder vote on January 13 will determine if Semler Scientific and Strive proceed with a merger, potentially positioning the combined entity as a significant player in Bitcoin reserves with approximately 13,000 BTC [1][3]. Group 1: Merger Details - The merger, first announced in September 2025, is an all-stock transaction that combines Strive, a Bitcoin treasury vehicle, with Semler, a smaller public company involved in health diagnostics and Bitcoin holdings [2]. - Strive has committed to substantial Bitcoin purchases, which will significantly increase the combined treasury beyond the previously reported 10,900 BTC to an estimated 13,000 BTC post-merger [3]. Group 2: Shareholder Engagement - Eric Semler, the founder of Semler, is actively encouraging shareholders to support the merger, framing the vote as a pivotal moment for the company's transition into a crypto-focused strategic reserve [4]. - Under the merger agreement, Semler stockholders will receive 21.05 shares of Strive ($ASST) for each share of Semler ($SMLR) [3]. Group 3: Market Context - Both companies' stocks are currently under market scrutiny, with Strive's shares fluctuating between approximately $0.85 and $1.08, while Semler's shares are experiencing pressure related to the implied acquisition value [5].

Core Insights - The PRIME study, a significant research initiative on preterm birth, has been accepted for publication in a peer-reviewed journal, following its presentation at a medical conference earlier this year [1][2] - Sera Prognostics, Inc. focuses on enhancing maternal and neonatal health through innovative pregnancy biomarker information [1][3] Company Overview - Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company's PreTRM Test is the only broadly validated, commercially available blood-based biomarker test for early risk prediction of spontaneous preterm birth [4] Product Details - The PreTRM Test analyzes proteins in the blood to predict preterm birth risk in asymptomatic singleton pregnancies, allowing for informed clinical decisions [4] - The test is ordered by medical professionals and provides risk assessments during weeks 18 to 20 of pregnancy [4]

Core Insights - Sera Prognostics Inc. will report its third quarter fiscal year 2025 financial results on November 13, 2025, followed by a conference call to discuss operational highlights and financial results [1][2] Company Overview - Sera Prognostics is dedicated to improving maternal and neonatal health through innovative pregnancy biomarker information, aiming to reduce healthcare delivery costs [3] - The company has a robust pipeline of diagnostic tests focused on early prediction of preterm birth risk and other pregnancy complications [3] - The PreTRM® Test is a key product that provides individualized risk predictions for spontaneous preterm birth, allowing for proactive interventions [5] Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is the leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Core Viewpoint - Sera Prognostics Inc. has appointed Dr. Tiffany Inglis as Chief Medical Officer to enhance its leadership in women's health diagnostics, particularly focusing on improving maternal and neonatal health through innovative pregnancy biomarker testing [1][2][3]. Company Overview - Sera Prognostics is dedicated to improving the lives of women and babies through precision pregnancy care, aiming to provide early and pivotal pregnancy information to enhance maternal and neonatal health and reduce healthcare delivery costs [4]. Leadership Appointment - Dr. Tiffany Inglis brings extensive clinical leadership experience from Elevance Health and Carelon Health, where she focused on women's and children's health, improving access to quality care while achieving cost savings [2][3]. - Her clinical expertise and experience with major payer networks position her well to lead Sera's clinical operations during a critical phase, including the upcoming publication of the PRIME study and pilot programs with state Medicaid [3][4]. Product Focus - Sera's PreTRM® Test is a blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies, allowing for informed clinical decisions [6][7]. - The test measures proteins in the blood that are highly predictive of preterm birth, enabling identification of at-risk women between 18 and 20 weeks of pregnancy [6][7]. Industry Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [5]. - The healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [5].

Core Insights - Sera Prognostics Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 5, 2025, highlighting the company's latest achievements [1] - The company focuses on improving maternal and neonatal health through innovative pregnancy biomarker information [1][3] Company Overview - Sera Prognostics is dedicated to enhancing the lives of women and babies via precision pregnancy care, aiming to provide early pregnancy information to improve health outcomes and reduce healthcare costs [3] - The company has a robust pipeline of diagnostic tests, particularly the PreTRM® Test, which predicts the risk of spontaneous premature delivery [3][5] Preterm Birth Context - Preterm birth, defined as any birth before 37 weeks' gestation, is a leading cause of illness and death in newborns, with over 10% of infants born prematurely in the U.S. for the last six years [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4] PreTRM® Test Details - The PreTRM® Test is the only broadly validated blood-based biomarker test that provides early and accurate risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [5] - This test allows physicians to identify women at increased risk for preterm birth between weeks 18 and 20 of pregnancy, facilitating personalized clinical decisions [5]

Core Insights - Sera Prognostics Inc. reported a revenue of $17,000 for Q2 2025, a decrease from $24,000 in Q2 2024, while total operating expenses remained flat at $9.3 million [4][6] - The company is focusing on commercial momentum following the completion of its pivotal PRIME study, which is expected to enhance engagement with managed Medicaid and other organizations [3][9] - The net loss for the quarter was $8.0 million, slightly improved from $8.3 million in the same period last year, with cash reserves of approximately $108.5 million expected to support operations through 2028 [6][15] Financial Performance - Revenue for Q2 2025 was $17,000, down from $24,000 in Q2 2024 [4] - Total operating expenses were $9.3 million, consistent with the previous year [4] - Research and development expenses decreased by approximately 24% to $3.3 million, attributed to lower clinical study costs [4] - Selling, general, and administrative expenses increased to $6.0 million from $4.9 million, reflecting investments in commercial activities [5] - The net loss for the quarter was $8.0 million, compared to $8.3 million a year ago [6] Strategic Initiatives - The company is engaging Medicaid plans in targeted states, particularly those with high premature birth rates, to capitalize on commercial opportunities [9] - Sera Prognostics plans to publish full results of the PRIME study this year, along with additional data on health economic benefits and expected cost savings [9] - Recent leadership appointments aim to strengthen the company's commercial capabilities and investor relations [9] Product Overview - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth, allowing for earlier interventions [12] - The test is designed to provide individualized risk assessments during weeks 18 to 20 of pregnancy, enabling personalized clinical decisions [12]

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its second quarter fiscal year 2025 financial results on August 6, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release detailing the financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth, defined as birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]

Core Insights - Sera Prognostics Inc. is focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information [4] - The company will participate in two upcoming investor conferences, the William Blair 45th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference, both taking place from June 3 to June 5, 2025 [1][2] Company Overview - Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [4] - The company's mission is to provide early, pivotal pregnancy information to enhance the health of mothers and newborns, aiming to reduce healthcare delivery costs [4] - Sera has a robust pipeline of innovative diagnostic tests, particularly focused on early prediction of preterm birth risk and other pregnancy complications [4] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns [5] - The March of Dimes Report Card indicates that over one in ten infants in the U.S. has been born prematurely for the last six consecutive years [5] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion for 2016 [5] PreTRM® Test Details - The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides early, accurate, and individualized risk predictions for spontaneous preterm birth in asymptomatic singleton pregnancies [6] - This test measures and analyzes proteins in the blood that are highly predictive of preterm birth, allowing physicians to identify women at increased risk during weeks 18 through 20 of pregnancy [6] - The PreTRM® Test enables more informed, personalized clinical decisions based on each woman's individual risk [6]

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its first quarter fiscal year 2025 financial results on May 7, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release with financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth is defined as any birth before 37 weeks' gestation and is a leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs for managing complications of prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]